Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 11,728 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level A Clear all
Completed Phase 1 Interventional

Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer

NCT00322751
View directory record Official record
Conditions
Lung Cancer
Interventions
Topotecan
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jan 7, 2010 · Synced Oct 21, 2026, 5:54 AM EDT
Terminated Phase 1 Interventional Results available

Efficacy, Safety And Tolerability Of PF-06743649 In Gout Subjects.

NCT02187029
View directory record Official record
Conditions
Gout
Interventions
PF-06743649, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Miami, Florida • South Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2016 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

NCT02983045
View directory record Official record
Conditions
Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Triple Negative Breast Cancer, HR+/HER2- Breast Cancer, Gastric Cancer
Interventions
Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab, Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
557 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
22
States / cities
La Jolla, California • Los Angeles, California • Stanford, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 1 Interventional

Trial to Study the Effect of CVL-231 on 24-Hour Ambulatory Blood Pressure in Participants With Schizophrenia

NCT05245539
View directory record Official record
Conditions
Blood Pressure, Schizophrenia
Interventions
CVL-231
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
30 Years to 60 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
10
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Long Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Not applicable Interventional Results available

Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function

NCT02469077
View directory record Official record
Conditions
Chronic Pain
Interventions
6 week aerobic exercise intervention, Placebo, Morphine, naloxone
Behavioral · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Chicago, Illinois • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pragmatic Trial of WHT vs. PC-GE to Promote Non-Pharmacological Strategies to Treat Chronic Pain in Veterans

NCT04330365
View directory record Official record
Conditions
Chronic Pain
Interventions
Whole Health Team (WHT) Intervention Arm, Primary Care Group Education (PC-GE) Intervention Arm, Usual Primary Care (UPC) Arm
Behavioral
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
6
States / cities
San Francisco, California • West Haven, Connecticut • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 21, 2026, 5:54 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Peripheral Immune System in Individuals With Schizophrenia

NCT05109065
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
SCID (Standardized Clinical Interview for DSM-V), PSS (Perceived Stress Score), Urine Toxicology Screen, Vitals, Blood Work, PQ-B, COVID Screening, Positive and Negative Syndrome Scale (PANSS)
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 40 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 2 Interventional

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

NCT00718692
View directory record Official record
Conditions
Immune Thrombocytopenic Purpura
Interventions
Sym001
Drug
Lead sponsor
Symphogen A/S
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
3
States / cities
Omaha, Nebraska • Philadelphia, Pennsylvania • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 30, 2019 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 2 Interventional

Thrust Manipulation Versus Non-Thrust Manipulation

NCT01438203
View directory record Official record
Conditions
Mechanical Low Back Pain
Interventions
Thrust manipulation, Non-thrust manipulation
Procedure
Lead sponsor
Walsh University
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
North Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 5, 2012 · Synced Oct 21, 2026, 5:54 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

NCT06660173
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Maridebart Cafraglutide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
409 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
28
States / cities
Birmingham, Alabama • Anaheim, California • Canoga Park, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 21, 2026, 5:54 AM EDT
Recruiting No phase listed Observational

The Study of Urinary Biomarkers in Patients With Hypomagnesemia

NCT07056283
View directory record Official record
Conditions
Hypomagnesemia
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 24, 2025 · Synced Oct 21, 2026, 5:54 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Revumenib and Mezigdomide in People With Leukemia

NCT07356154
View directory record Official record
Conditions
Leukemia, Acute Leukemia, Relapse Leukemia, Refractory Leukemia, Refractory Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia
Interventions
Revumenib, Mezigdomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
10
States / cities
Duarte, California • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 1 Interventional

Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma

NCT00613054
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Zactima, Gleevec, Hydroxyurea
Drug
Lead sponsor
Annick Desjardins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2012 · Synced Oct 21, 2026, 5:54 AM EDT
Recruiting Not applicable Interventional

Honest, Open, Proud (HOP): A Peer Delivered, Co-occurring Disorders Intervention for Justice-involved Veterans

NCT07742722
View directory record Official record
Conditions
Stigma, Co-Occurring Disorders, Substance Use Disorder, Mental Health Disorder, Veterans
Interventions
Veterans Affairs-Honest, Open, Proud
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bedford, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 1 Interventional

Study of TCP-ATRA for Adult Patients With AML and MDS

NCT02273102
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Leukemia
Interventions
Tranylcypromine, Tretinoin
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Oct 21, 2026, 5:54 AM EDT
Recruiting Not applicable Interventional

Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Small Tonsils

NCT06258837
View directory record Official record
Conditions
Otolaryngological Disease, Obstructive Sleep Apnea
Interventions
DISE-Directed Surgery, Adenotonsillectomy
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
2 Years to 17 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Ann Arbor, Michigan • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 21, 2026, 5:54 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Investigating the Effectiveness of 2 Different Doses of BIOHM FX Probiotic Blend in Improving Digestive Symptoms

NCT06782945
View directory record Official record
Conditions
Moderate Gastrointestinal Discomfort
Interventions
BIOHM FX Probiotic Blend
Dietary Supplement
Lead sponsor
Biohm Technologies
Industry
Eligibility
18 Years to 75 Years
Enrollment
141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2025 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 1 Interventional

Multi-center, Open-label, Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04045795
View directory record Official record
Conditions
Multiple Myeloma
Interventions
isatuximab SAR650984 IV, pomalidomide, dexamethasone, isatuximab SAR650984 SC, Investigational injector device
Drug · Device
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
Gilbert, Arizona • Duarte, California • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer

NCT00887575
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, Carboplatin, Sunitinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
14
States / cities
Fort Lauderdale, Florida • Fort Myers, Florida • Gainesville, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2016 · Synced Oct 21, 2026, 5:54 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma

NCT04722601
View directory record Official record
Conditions
Follicular Lymphoma
Interventions
Venetoclax, Obinutuzumab, CC-486
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 21, 2026, 5:54 AM EDT
Active, not recruiting Phase 1 Interventional

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

NCT02659930
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
liposomal doxorubicin, pomalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 21, 2026, 5:54 AM EDT
Recruiting Not applicable Interventional

Sacramento Clinical High Risk for Psychosis Stepped-Care Program

NCT06640803
View directory record Official record
Conditions
Clinical High Risk for Psychosis, Ultra High Risk for Psychosis
Interventions
Stepped-Care including Cognitive Behavioral Case Management
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
12 Years to 25 Years
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
6
States / cities
Elk Grove, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intracervical Lidocaine Gel for IUD Insertional Pain

NCT01214161
View directory record Official record
Conditions
Pain
Interventions
2% lidocaine gel, placebo
Drug · Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 21, 2026, 5:54 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability, PK, ECG Effects, Food Effect, and Drug-drug Interaction (DDI) of Hormonal Contraceptives of PTI-428 in Healthy Female Volunteers

NCT02846142
View directory record Official record
Conditions
Healthy Volunteer
Interventions
PTI-428, Placebo, ethinyl estradiol and levonorgestrel
Drug · Other
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 21, 2026, 5:54 AM EDT